Home › Funds › IRIDIAN ASSET MANAGEMENT LLC/CT › BCTXL

IRIDIAN ASSET MANAGEMENT LLC/CT position in BCTXL

BRIACELL THERAPEUTICS CORP · Health Care

IRIDIAN ASSET MANAGEMENT LLC/CT reported holding 65,000 shares of BCTXL (BRIACELL THERAPEUTICS CORP) in its Q3 2026 13F filing — a position valued at US$75K, representing 0.03% of its reported portfolio and ranking #41 among its reported holdings. IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed BCTXL holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)65.00K sh
Reported value held$75.40K
Portfolio Weight0.03%
First reportedQ1 2026
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How IRIDIAN ASSET MANAGEMENT LLC/CT's BCTXL position evolved

IRIDIAN ASSET MANAGEMENT LLC/CT first disclosed a stake in BCTXL in Q1 2026 at 65,000 shares (US$67K). The position peaked in Q3 2026 at 65,000 shares, worth US$75K. Across 3 filings, IRIDIAN ASSET MANAGEMENT LLC/CT held the position steady without any share-count change. The most recent filing (Q3 2026) shows 65,000 shares valued at US$75K.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 65.00K $66.96K New
Q2 2026 65.00K $57.85K Hold
Q3 2026 65.00K $75.40K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCTXL and 13F data

BCTXL (BRIACELL THERAPEUTICS CORP) is a Health Care company. 10 other funds we track also report a position in BCTXL — the largest reported positions include Empery Asset Management, LP (US$267K), SABBY MANAGEMENT, LLC (US$158K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCTXL

All BCTXL fund holders →

FAQ

How long has IRIDIAN ASSET MANAGEMENT LLC/CT held BCTXL?

IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed BCTXL holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is IRIDIAN ASSET MANAGEMENT LLC/CT's current position in BCTXL?

As of Q3 2026, IRIDIAN ASSET MANAGEMENT LLC/CT holds 65.00K shares of BCTXL (BRIACELL THERAPEUTICS CORP), valued at $75.40K, representing 0.03% of its reported portfolio and ranking #41.

Has IRIDIAN ASSET MANAGEMENT LLC/CT been buying or selling BCTXL?

In the latest 13F filing (Q3 2026), IRIDIAN ASSET MANAGEMENT LLC/CT held unchanged its position in BCTXL. The position peaked in Q3 2026 at 65.00K shares.

Which other funds hold BCTXL?

Other major institutional holders of BCTXL include Empery Asset Management, LP, SABBY MANAGEMENT, LLC, among 10 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.